---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-017558"
form_type: "8-K"
ticker: "LIXT"
cik: "0001335105"
company_name: "LIXTE BIOTECHNOLOGY HOLDINGS, INC."
filed_at: "2022-06-23T23:59:59+00:00"
generated_at: "2026-06-24T23:35:01.331120+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Lixte appoints Bas van der Baan as independent director; grants 250K options at $0.74

## Summary
- Effective June 17, 2022, Bastiaan van der Baan appointed to Board as independent director.
- van der Baan brings 20+ years biotech oncology/diagnostics experience to clinical-stage LB-100 development.
- Granted options for 250,000 shares at $0.74 (closing price on grant date), 5-year term.
- Options vest 50% immediately, then 12.5% quarterly over four quarters, subject to continued service.

## SEC filing metadata
- accession: 0001493152-22-017558
- form_type: 8-K
- ticker: LIXT
- cik: 0001335105
- company_name: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- filed_at: 2022-06-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1335105/000149315222017558/0001493152-22-017558-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1335105/000149315222017558/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-017558
- JSON: https://secwatch.observer/filing/0001493152-22-017558.json
- Plain text: https://secwatch.observer/filing/0001493152-22-017558.txt

## Key facts
- Executive change
  Bastiaan van der Baan was appointed as Director at LIXTE BIOTECHNOLOGY HOLDINGS, INC..
  - Action: appointed
  - Role: Director
  source text: Effective as of June 17, 2022, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc. (the “Company”) appointed Bastiaan van der Baan to the Board as an independent director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1335105/000149315222017558/0001493152-22-017558-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.